Buske C et al. Ibrutinib treatment in Waldenström’s macroglobulinemia: Follow-up efficacy and safety from the iNNOVATETM study. Proc ASH 2018;Abstract 149.
Bustoros M et al. Progression risk stratification of asymptomatic Waldenström macroglobulinemia. J Clin Oncol 2019;37(16):1403-11. Abstract
Castillo JJ et al. Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study. Blood 2019;133(4):299-305. Abstract
Castillo JJ et al. Ibrutinib dose reduction does not affect progression-free survival in patients with Waldenstrom macroglobulinemia. Proc ASH 2018;Abstract 1598.
Castillo JJ et al. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica 2018;103(7):e307-10. Abstract
Castillo JJ et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica 2018;103(10):e466-8. Abstract
Castillo JJ et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Proc ASH 2018;Abstract 2888.
Castillo JJ et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenström macroglobulinemia. Clin Cancer Res 2018;24(14):3247-52. Abstract
Castillo JJ et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol 2018;181(1):77-85. Abstract
Castillo JJ, Treon SP. Initial evaluation of the patient with Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018;32(5):811-20. Abstract
Dimopoulos MA, et al; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med 2018;378(25):2399-410. Abstract
Gavriatopoulou M et al. How I treat rituximab refractory patients with WM. Oncotarget 2018;9(96):36824-5. Abstract
Gavriatopoulou M et al. Ibrutinib for rituximab-refractory Waldenström macroglobulinemia. Oncotarget 2017;9(16):12536-7. Abstract
Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019;94(2):266-76. Abstract
Gertz MA. Selecting initial therapy for newly diagnosed Waldenström macroglobulinemia. J Clin Oncol 2018;36(27):2749-51. Abstract
Gertz MA. Waldenström macroglobulinemia treatment algorithm 2018. Blood Cancer J 2018;8(4):40. Abstract
Gustine JN et al. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol 2019;184(2):242-5. Abstract
Gustine JN et al. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol 2018;93(4):511-7. Abstract
Kastritis E et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(5):860-2. Abstract
Kastritis E, Dimopoulos MA. Proteasome inhibitors in Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018;32(5):829-40. Abstract
Sklavenitis-Pistofidis R et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood 2018;132(24):2608-12. Abstract
Treon SP et al. Genomic landscape of Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018;32(5):745-52. Abstract
Treon SP et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol 2018;36(27):2755-61. Abstract
Treon SP et al. MYD88 wild-type Waldenstrom macroglobulinaemia: Differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol 2018;180(3):374-80. Abstract
Treon SP, Castillo JJ. The real world of Waldenström’s macroglobulinaemia. Lancet Haematol 2018;5(7):e275-6. Abstract